These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

587 related articles for article (PubMed ID: 22266934)

  • 21. Laparoscopy to Predict the Result of Primary Cytoreductive Surgery in Patients With Advanced Ovarian Cancer: A Randomized Controlled Trial.
    Rutten MJ; van Meurs HS; van de Vrie R; Gaarenstroom KN; Naaktgeboren CA; van Gorp T; Ter Brugge HG; Hofhuis W; Schreuder HW; Arts HJ; Zusterzeel PL; Pijnenborg JM; van Haaften M; Fons G; Engelen MJ; Boss EA; Vos MC; Gerestein KG; Schutter EM; Opmeer BC; Spijkerboer AM; Bossuyt PM; Mol BW; Kenter GG; Buist MR
    J Clin Oncol; 2017 Feb; 35(6):613-621. PubMed ID: 28029317
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Influence of residual tumor on outcome in ovarian cancer patients with FIGO stage IV disease: an exploratory analysis of the AGO-OVAR (Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group).
    Wimberger P; Wehling M; Lehmann N; Kimmig R; Schmalfeldt B; Burges A; Harter P; Pfisterer J; du Bois A
    Ann Surg Oncol; 2010 Jun; 17(6):1642-8. PubMed ID: 20165986
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Outcomes and patterns of secondary relapse in platinum-sensitive ovarian cancer: implications for tertiary cytoreductive surgery.
    Tang J; Liu DL; Shu S; Tian WJ; Liu Y; Zang RY
    Eur J Surg Oncol; 2013 Jul; 39(7):786-91. PubMed ID: 23490332
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study.
    Winter WE; Maxwell GL; Tian C; Sundborg MJ; Rose GS; Rose PG; Rubin SC; Muggia F; McGuire WP;
    J Clin Oncol; 2008 Jan; 26(1):83-9. PubMed ID: 18025437
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The effect of lymphadenectomy in advanced ovarian cancer according to residual tumor status: A population-based study.
    Zhou J; Zhang WW; Zhang QH; He ZY; Sun JY; Chen QH; Wu SG
    Int J Surg; 2018 Apr; 52():11-15. PubMed ID: 29432972
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognostic significance of normal-sized ovary in advanced serous epithelial ovarian cancer.
    Paik ES; Kim JH; Kim TJ; Lee JW; Kim BG; Bae DS; Choi CH
    J Gynecol Oncol; 2018 Jan; 29(1):e13. PubMed ID: 29185271
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The addition of extensive upper abdominal surgery to achieve optimal cytoreduction improves survival in patients with stages IIIC-IV epithelial ovarian cancer.
    Eisenhauer EL; Abu-Rustum NR; Sonoda Y; Levine DA; Poynor EA; Aghajanian C; Jarnagin WR; DeMatteo RP; D'Angelica MI; Barakat RR; Chi DS
    Gynecol Oncol; 2006 Dec; 103(3):1083-90. PubMed ID: 16890277
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of residual tumor locations in advanced ovarian cancer patients after incomplete primary cytoreduction.
    Grabowskil JP; Mardas M; Markowska A; Markowska J
    Eur J Gynaecol Oncol; 2015; 36(3):274-7. PubMed ID: 26189252
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Patterns of Recurrence and Clinical Outcome of Patients With Stage IIIC to Stage IV Epithelial Ovarian Cancer in Complete Response After Primary Debulking Surgery Plus Chemotherapy or Neoadjuvant Chemotherapy Followed by Interval Debulking Surgery: An Italian Multicenter Retrospective Study.
    Gadducci A; Cosio S; Zizioli V; Notaro S; Tana R; Panattoni A; Sartori E
    Int J Gynecol Cancer; 2017 Jan; 27(1):28-36. PubMed ID: 27870700
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial.
    Harter P; du Bois A; Hahmann M; Hasenburg A; Burges A; Loibl S; Gropp M; Huober J; Fink D; Schröder W; Muenstedt K; Schmalfeldt B; Emons G; Pfisterer J; Wollschlaeger K; Meerpohl HG; Breitbach GP; Tanner B; Sehouli J; ;
    Ann Surg Oncol; 2006 Dec; 13(12):1702-10. PubMed ID: 17009163
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The prognostic relevance of node metastases in optimally cytoreduced advanced ovarian cancer.
    Bachmann C; Brucker SY; Kraemer B; Rothmund R; Staebler A; Fend F; Wallwiener D; Grischke EM
    J Cancer Res Clin Oncol; 2015 Aug; 141(8):1475-80. PubMed ID: 25739827
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The benefits of low anterior en bloc resection as part of cytoreductive surgery for advanced primary and recurrent epithelial ovarian cancer patients outweigh morbidity concerns.
    Park JY; Seo SS; Kang S; Lee KB; Lim SY; Choi HS; Park SY
    Gynecol Oncol; 2006 Dec; 103(3):977-84. PubMed ID: 16837030
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic significance of residual tumor in patients with epithelial ovarian carcinoma stage IV in a 20 year perspective.
    Elstrand MB; Sandstad B; Oksefjell H; Davidson B; Tropé CG
    Acta Obstet Gynecol Scand; 2012 Mar; 91(3):308-17. PubMed ID: 22050605
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: a prospective study.
    Eisenkop SM; Friedman RL; Wang HJ
    Gynecol Oncol; 1998 May; 69(2):103-8. PubMed ID: 9600815
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The impact of pelvic retroperitoneal invasion and distant nodal metastases in epithelial ovarian cancer.
    Pereira A; Pérez-Medina T; Magrina JF; Magtibay PM; Rodríguez-Tapia A; Pérez-Milán F; Ortiz-Quintana L
    Surg Oncol; 2014 Mar; 23(1):40-4. PubMed ID: 24183480
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prognostic and Predictive Value of the Peritoneal Cancer Index in Primary Advanced Epithelial Ovarian Cancer Patients After Complete Cytoreductive Surgery: Study of Tumor Bank Ovarian Cancer.
    Gasimli K; Braicu EI; Richter R; Chekerov R; Sehouli J
    Ann Surg Oncol; 2015 Aug; 22(8):2729-37. PubMed ID: 25672560
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer.
    Bristow RE; Montz FJ; Lagasse LD; Leuchter RS; Karlan BY
    Gynecol Oncol; 1999 Mar; 72(3):278-87. PubMed ID: 10053096
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The influence of tumor grade, distribution, and extent of carcinomatosis in minimal residual stage III epithelial ovarian cancer after optimal primary cytoreductive surgery.
    Farias-Eisner R; Teng F; Oliveira M; Leuchter R; Karlan B; Lagasse LD; Berek JS
    Gynecol Oncol; 1994 Oct; 55(1):108-10. PubMed ID: 7959250
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Introduction of staging laparoscopy in the management of advanced epithelial ovarian, tubal and peritoneal cancer: impact on prognosis in a single institution experience.
    Fagotti A; Vizzielli G; Fanfani F; Costantini B; Ferrandina G; Gallotta V; Gueli Alletti S; Tortorella L; Scambia G
    Gynecol Oncol; 2013 Nov; 131(2):341-6. PubMed ID: 23938372
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Appropriate Recommendations for Surgical Debulking in Stage IV Ovarian Cancer.
    Chern JY; Curtin JP
    Curr Treat Options Oncol; 2016 Jan; 17(1):1. PubMed ID: 26714493
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 30.